By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Neurocrine Biosciences, Inc. 

12790 El Camino Real

San Diego  California  92121  U.S.A.
Phone: 858-617-7600 Fax: 858-617-7601


SEARCH JOBS








Company News
Neurocrine Biosciences (NBIX) Release: SoCal Biotech's Tourette Drug Flunks Phase II Study 1/18/2017 5:31:04 AM
Neurocrine Biosciences (NBIX) Announces The Appointment Of David-Alexandre Gros M.D. President And Chief Operating Officer 1/6/2017 8:24:50 AM
Neurocrine Biosciences (NBIX) Provides Update On FDA Advisory Committee For INGREZZA (Valbenazine) For The Treatment Of Tardive Dyskinesia 1/6/2017 7:55:59 AM
Neurocrine Biosciences (NBIX) Announces Chief Financial Officer Timothy P. Coughlin To Step Down 12/22/2016 12:39:45 PM
Neurocrine Biosciences (NBIX) Announces FDA Advisory Committee Meeting To Review INGREZZA (Valbenazine) New Drug Application For The Treatment Of Tardive Dyskinesia 11/30/2016 10:12:21 AM
Neurocrine Biosciences (NBIX) Reports Third Quarter 2016 Results 11/3/2016 9:18:42 AM
Neurocrine Biosciences (NBIX) Announces INGREZZA (Valbenazine) New Drug Application For The Treatment Of Tardive Dyskinesia Has Been Accepted For Priority Review By U.S. FDA 10/11/2016 6:47:07 AM
Neurocrine Biosciences (NBIX) To Present At The Morgan Stanley Global Healthcare Conference 9/8/2016 10:02:24 AM
Neurocrine Biosciences (NBIX) To Present At The Baird 2016 Healthcare Conference 9/2/2016 6:53:35 AM
Neurocrine Biosciences (NBIX) Announces FDA Conditional Acceptance Of Proprietary Name INGREZZA For VMAT2 Inhibitor Valbenazine 9/1/2016 8:12:02 AM
12345678910...
//-->